AAPP members are invited to participate in an Open-Label Survey of Onemia™ – the first medical application of krill concentrates.
With your participation you will receive: Free Product, AAPP annual membership fee*, Free Advanced Lipid Tests*, Added practice revenue stream possible
* Conditions for qualification apply
Participate in the Survey to evaluate the efficacy of Onemia™, a krill sourced omega-3 phospholipid concentrate, in managing omega-3 phospholipid deficiency manifested as hypertriglyceridemia, mixed dyslipidemia, and metabolic disorders.
Minimal documentation is required; one-page NDA, one-page patient informed consent form, a copy of patients’ identity-blinded basic lipid panel results (Baseline and 90-day); advanced tests are welcomed and encouraged.
| Design:
|
- Open label survey
- Number of patients: 10
- Treatment period: 90 days (earlier results are welcome)
|
Subjects:
|
- Mixed dyslipidemia (TGs > 200 mg/dL) (Obligatory)
- Statin resistant / intolerant, or not at LDL goal
- Lovaza® users / candidates
- Cardio-Metabolic Syndrome
|
| Outcome measures:
|
- Plasma lipid profile (LDL-C , HDL-C, TGs) – when possible, Pattern “B”/LDL-C, Lp(a), etc.
- Inflammation (hs-CRP, LpPLA2 , MPO,) – when possible
- HbA1c, Glucose & insulin – when possible
|
To begin Survey contact: Michel Lockhart
Telephone: 450-686-4555 x 407
Email: m.lockhart@acastipharma.com
Fax: (450) 686-2505
Marine-sourced omega-3 fatty acids help lower risk of cardiovascular disease as per the American Heart Association recommendation of 2 to 4 g of eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA) – Omega-3 per day, for patients requiring a reduction in their triglyceride level. (1) This and most others have focused in marine-sourced omega-3 fatty acid research on fish and fish oils.
Krill omega-3 is now emerging as the next generation leader in marine-sourced omega-3. This is primarily due to research suggesting krill oil’s more effective/efficient delivery of omega-3, and its ability to positively address more parameters of the lipid profile, and other cardiovascular risk factors. (2, 3)
Onemia™’s composition and molecular structure are significantly different to that of fish oil, pointing to unique clinical benefits. In fish, the long-chain polyunsaturated fatty acids of the omega-3s (EPA/DHA) are attached to triglycerides. In Onemia™, they are attached to phospholipids, mostly phosphatidylcholine, thus providing better absorption in plasma and red blood cells. Furthermore, phospholipids are the major component of cell membranes and essential for all vital cell processes. They are one of the principle constituents of High Density Lipoprotein (HDL) and play, as such, an important role in modulating cholesterol efflux. Onemia™ also contains the carotenoid astaxanthin, a potent antioxidant clinically proven to be significantly more potent than most recognized antioxidants like vitamin E, CoQ10 and lycopene. Fish oil does not contain antioxidants, which explains their vulnerability to oxidation partly responsible for the unpleasant aftertaste which in turn leads to reduced compliance. The phospholipids in Onemia™ facilitate absorption and bioavailability of omega-3s and antioxidants. Continue reading →
The beginning of 2012 is a perfect time to evaluate last year’s strengths and weaknesses and reflect on your practice’s marketing goals for the coming year.
